Back

Efficacy and safety of reduced-dose and slow-infusion intravenous alteplase regimen in patients with acute pulmonary embolism at intermediate-high-risk

31 August 2024 (17:00 - 17:10)
Organised by: Logo
Congress Presentation Part of: Acute pulmonary embolism: new approaches for an old killer Pulmonary Embolism (PE) ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Barkin Kultursay

Tunceli State Hospital, Tunceli (Turkiye)

5 More presentations in this session

Presentation thumbnail
Elective endovascular reperfusion therapies in intermediate-high risk pulmonary embolism after PERT assesment
Doctor I. Cigalini (Rosario, AR)
Abstract Slides Video
Presentation thumbnail
Impact of a blood return system on mechanical thrombectomy in treatment of acute pulmonary embolism: a retrospective cohort study comparing 30-day mortality and need for blood transfusion
Doctor D. Patel (Cleveland, US)
Abstract Slides Video
Presentation thumbnail
Intracranial haemorrhage following treatment for pulmonary embolism: analysis of the german nationwide inpatient sample
Mr K. Christodoulou (Mainz, DE)
Abstract Slides Video
Presentation thumbnail
White Smoke in the Intermediate risk PE debate, could POPE be the solution?
Doctor A. Martins (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Interleukin 21, plasminogen activator inhibitor 1 and fractalkine improve risk stratification in elderly patients with pulmonary embolism
Mr M. Matter (Zurich, CH)
Abstract Slides Video

Access the full session

Session thumbnail
Acute pulmonary embolism: new approaches for an old killer
Video

The Event

Event poster

ESC Congress 2024

31 August 2024 17:00 CET
You may be interested in
thumbnail
Congress Session
Interventional therapies in acute pulmonary embolism
thumbnail
Congress Presentation
Standard-dose tPA vs. slow-infusion tPA vs. catheter-guided low-dose tPA in the treatment of patients with intermediate-high-risk pulmonary embolism
thumbnail
Congress Session
Acute pulmonary embolism: new approaches for an old killer

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources